Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
Status:
Active, not recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This study seeks to determine the efficacy of tocilizumab (TCZ) in patients with
hemophagocytic lymphohistiocytosis (HLH) and high cytokine levels (proteins involved in
inflammation) in an attempt to decrease the damage caused by these proteins; and secondarily
to assess its safety and impact on disease activity.